Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for urinary incontinence due to neurogenic detrusor overactivity
NL-OMON47110Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in detrusor hyperreflexia (DH) (3 arms), sponsored by Ipsen. Primary endpoint: Mean change in weekly urinary incontinence episodes. Started Apr 2017; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on NL-OMON47110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47110.